The design of inhibitors that hit the diverse domains involved in the execution of the activities HDAC6 exert in GBM cells could greatly enhance selectivity, whereas potency could be powered by adducts targeting GBM subtype-specific molecular signatures while penetrating the BBB. The gene discussed is HDAC6; the disease is glioblastoma.